Skip to main content
xMedica

NCT07784725ClinicalTrials.gov

A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus

A Phase III Randomised, Double-Blind, Placebo-Controlled Multicentre Trial to Evaluate the Efficacy and Safety of AZD6234 in Participants With Obesity or Overweight With at Least One Weight-Related Comorbidity Without Type 2 Diabetes Mellitus (SELENE 1)

RecruitingTaking participants now, according to the registry record.
Contact this study

In brief

The study will evaluate how well AZD6234 works and how safe it is in adults with excess weight or obesity. Efficacy of AZD6234 will be compared to placebo in percent body weight change from baseline at 68 weeks of treatment

Phase 32,500 participants sought220 sites16 countries

Categories

Registered in 1 registry

One study can be registered in several registries. We show it once and link every record we hold.

Trial information is shown as published by the registry, in its original language.

Interested in this study?

Sign in or create an account to register your interest and follow this study.

How this study is set up

The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.

  • Not stated: Registered after enrolment began (about 6 days after the recorded start)First posted 2026-08-25; recorded start 2026-08-19
  • Present: Has a defined primary outcomeA primary outcome measure is listed in the record
  • Present: The primary outcome states a time frameThe primary outcome measure records a time frame
  • Present: Participants are randomly assignedAllocation is recorded as randomised
  • Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
  • Present: Uses blinding (masking)A masking level is recorded in the record
  • Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
  • Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
  • Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
  • Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
  • Present: Sponsor has 1038 other studies in this databaseCounted from the lead sponsor named in the record (AstraZeneca)
  • Present: Sponsor has posted results for at least one studyBased on the sponsor’s studies in this database
  • The record lists 1 condition.
  • Lead sponsor type recorded as: industry.
  • Intervention regulatory context: investigational, within a phased regulatory pathway.

Trial stature

Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.

Methodological rigourSTRONG

A strong methodological design for a phase 3 study, judged from its ClinicalTrials.gov record.

How this score is built
  • Randomised allocation20/20

    Participants are randomly allocated between arms

  • Blinding20/20

    Quadruple-blind

  • Control arm13/15

    Placebo / sham control arm

  • Primary-outcome specificity10/10

    Named primary outcome with a defined time frame

  • Endpoint type3/10

    Surrogate or intermediate endpoint (conservative default)

  • Multi-centre8/8

    Multi-centre: 212 sites

  • Data monitoring committee0/7

    No data monitoring committee stated

  • Prospective registration5/5

    Registered before the study start date

  • Protocol / SAP posted0/5

    No protocol or SAP posted to the registry

ScaleLARGE

A large study, international in scope: 2,500 participants (target), run at 220 sites, across 16 countries.

How this score is built
  • Enrolment34/40

    2,500 participants (target)

  • Site count25/25

    212 sites

  • Country count15/15

    16 countries

  • Planned duration8/10

    Planned over about 34 months

  • Sponsor scale10/10

    AstraZeneca has led 1,017 trials in our corpus

Investigator standingUNKNOWN

We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.

How this score is built
  • Investigator standing0/100

    No investigator recorded in the registry for this trial

These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.

Summary

The study will evaluate how well AZD6234 works and how safe it is in adults with excess weight or obesity. Efficacy of AZD6234 will be compared to placebo in percent body weight change from baseline at 68 weeks of treatment

This is a Phase III, global, randomised, parallel-group, double-blind, multicentre study to assess the efficacy and safety of AZD6234 compared with placebo, administered SC once weekly in adults with obesity or overweight with at least one weight-related comorbidity without T2DM. Eligible participants will be randomized to either receive AZD6234 or matching placebo respectively.

Conditions

  • Obesity or Overweight

Eligibility

Eligibility
SexAll
Ages18 Years – No maximum
Healthy volunteersNo

Eligibility as written in the registry

Inclusion Criteria: * Males \& females (inclusive of all gender identities) age ≥18 years * BMI ≥30 kg/m2 OR BMI ≥27 kg/m2 with at least one of the following weight related comorbidities (treated or untreated): hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, heart failure, chronic kidney disease, metabolic dysfunction-associated steatotic liver disease, osteoarthritis of the knee, or stress urinary incontinence * Stable body weight (≤5% body weight change) for at least 3 months prior to Randomisation * History of at least one self-reported unsuccessful attempt to lose body weight in their lifetime Exclusion Criteria: * Obesity primarily caused by other endocrine disorders * History of Type 1 or Type 2 Diabetes Mellitus, HbA1c ≥6.5% (48 mmol/mol), and/or treatment with glucose-lowering agent(s) within 3 months prior to Screening * Significant hepatobiliary disease and/or any of the following results at Screening: * ALT ≥ 3.0 × ULN * AST ≥ 3.0 × ULN * TBL \> 1.5 × ULN (except for cases of known Gilbert's Syndrome) * Has received treatment with a GLP-1 receptor agonist or GLP-1 containing medication for any indication within 3 months before Randomisation.

Eligibility in plain statements

This record's criteria have not been broken into separate statements yet. The registry text above is complete and is the authoritative version.

Study design

Study design
Study typeInterventional
PhasePhase 3
AllocationRandomised
Intervention modelPARALLEL
Primary purposeTREATMENT
MaskingQUADRUPLE (4)
Enrolment2,500 participants sought

Sponsor and collaborators

  • AstraZeneca Sponsor

Arms and interventions

  • AZD6234 Dose 1EXPERIMENTAL

    AZD6234 Dose 1

  • AZD6234 Dose 2EXPERIMENTAL

    AZD6234 Dose 2

  • PlaceboPLACEBO_COMPARATOR

    Matching placebo

Interventions

  • Drug Lenbelintide

    IMP injected subcutaneously, once a week. Unit dose strength as per CSP.

  • Drug Placebo

    Placebo matching IMP dose injected subcutaneously, once a week.

Outcome measures

  1. Primary outcome

    Percent change in body weight from baseline at 68 weeks of treatment

    To evaluate the effect of AZD6234 as compared to placebo in percent body weight change

    Time frame 68 weeks

  2. Secondary outcome

    Absolute change in weight (kg) from baseline at 68 weeks of treatment

    To evaluate the effect of AZD6234 as compared to placebo on absolute change in weight

    Time frame 68 weeks

  3. Secondary outcome

    Achievement of at least 5 % body weight loss from baseline at 68 weeks of treatment

    To evaluate the effect of AZD6234 as compared to placebo in body weight loss of at least 5%

    Time frame 68 weeks

  4. Secondary outcome

    Achievement of at least 10% body weight loss from baseline at 68 weeks of treatment

    To evaluate the effect of AZD6234 as compared to placebo in body weight loss of at least 10%

    Time frame 68 weeks

  5. Secondary outcome

    Change in waist circumference (cm) from baseline at 68 weeks of treatment

    To evaluate the effect of AZD6234 as compared to placebo on waist circumference change

    Time frame 68 weeks

  6. Secondary outcome

    Percent change in triglycerides from baseline at 68 weeks of treatment

    To evaluate the effect of AZD6234 as compared to placebo on triglycerides percent change

    Time frame 68 weeks

  7. Secondary outcome

    Change in systolic blood pressure (mmHg) from baseline at 68 weeks of treatment

    To evaluate the effect of AZD6234 as compared to placebo on systolic blood pressure change

    Time frame 68 weeks

  8. Secondary outcome

    Percent change in fat mass from baseline at 68 weeks of treatment measured by DXA in the DXA Sub-Study subset

    Body Composition Sub-study: To evaluate the effect of AZD6234 as compared to placebo on body composition change in the DXA subset of participants

    Time frame 68 weeks

Dates

Dates
Start dateAugust 19, 2026 (actual)
Primary completionAugust 11, 2028 (estimated)
CompletionMay 21, 2029 (estimated)
First postedAugust 25, 2026 (actual)
Last updatedOctober 30, 2026
Results postedNot stated in the registry record
Status last verifiedOctober 2026

Actual means the event happened. Estimated means the sponsor expects it. The two mean different things.

Locations

76 sites are recruiting

Argentina

Argentina
FacilityCityState or regionStatus
Research SiteBuenos AiresRecruiting
Research SiteBuenos AiresRecruiting
Research SiteCiudad de Buenos AiresRecruiting
Research SiteMendozaRecruiting
Research SiteRamos MejíaNot yet recruiting
Research SiteRosarioRecruiting
Research SiteSan NicolásNot yet recruiting

Australia

Australia
FacilityCityState or regionStatus
Research SiteBotanyRecruiting
Research SiteCamberwellRecruiting
Research SiteCharlestownRecruiting
Research SiteSt AlbansRecruiting
Research SiteSt LeonardsRecruiting
Research SiteWaitaraRecruiting

Brazil

Brazil
FacilityCityState or regionStatus
Research SiteBelo HorizonteNot yet recruiting
Research SiteBrasíliaNot yet recruiting
Research SiteCampinasNot yet recruiting
Research SiteCampinasNot yet recruiting
Research SiteCuritibaWithdrawn
Research SiteCuritibaNot yet recruiting
Research SiteCuritibaNot yet recruiting
Research SiteNatalNot yet recruiting
Research SitePorto AlegreNot yet recruiting
Research SiteRio de JaneiroNot yet recruiting
Research SiteSão José dos CamposNot yet recruiting
Research SiteSão PauloNot yet recruiting

Bulgaria

Bulgaria
FacilityCityState or regionStatus
Research SiteMontanaNot yet recruiting
Research SitePlevenNot yet recruiting
Research SitePlovdivRecruiting
Research SiteSofiaRecruiting
Research SiteSofiaRecruiting
Research SiteSofiaRecruiting
Research SiteVarnaNot yet recruiting
Research SiteYambolRecruiting

Canada

Canada
FacilityCityState or regionStatus
Research SiteBramptonOntarioRecruiting
Research SiteCalgaryAlbertaRecruiting
Research SiteGuelphOntarioRecruiting
Research SiteHamiltonOntarioRecruiting
Research SiteMississaugaOntarioRecruiting
Research SiteMonctonNew BrunswickRecruiting
Research SiteMontrealQuebecRecruiting
Research SiteNew WestminsterBritish ColumbiaRecruiting
Research SiteNorth YorkOntarioRecruiting
Research SiteQuébecQuebecRecruiting
Research SiteQuébecQuebecRecruiting
Research SiteSaint-Charles-BorroméeQuebecRecruiting
Research SiteScarborough VillageOntarioRecruiting
Research SiteSherbrookeQuebecRecruiting
Research SiteStoney CreekOntarioRecruiting
Research SiteStouffvilleOntarioRecruiting
Research SiteSurreyBritish ColumbiaWithdrawn

170 further sites are listed in the registry record.

Study documents

No documents are linked in this registry record.

Changes over time

  1. October 30, 2026

    Site added

    8 sites added (220 total)

    212220